Stock Events

Twist Bioscience 

$43.34
145
+$0.55+1.29% Friday 20:00

Statistics

Day High
44.46
Day Low
43.17
52W High
60.9
52W Low
14.42
Volume
315,617
Avg. Volume
875,603
Mkt Cap
2.53B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

15
NOV
Earnings
 

Earnings

15NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.47
-1.21
-0.95
-0.7
Expected EPS
-0.696245
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TWST. It's not an investment recommendation.
Alphabet
75333
GOOGL
Apple
65621
AAPL
Microsoft
61102
MSFT
Amazon
56572
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.93B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Twist Bioscience's synthetic DNA products.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers long-read sequencing technologies, competing with Twist Bioscience in the genomics and DNA sequencing market.
Agenus
AGEN
Mkt Cap111.1M
Agenus is involved in immuno-oncology, a field that relies on synthetic biology and genomics, areas where Twist Bioscience operates.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is focused on gene editing, a sector that directly competes with Twist Bioscience's synthetic DNA for research and therapeutic applications.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the gene editing space, competing with Twist Bioscience in the development of genomic tools and therapies.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing technology, competing with Twist Bioscience in the genomic medicine field.
Sangamo Therapeutics
SGMO
Mkt Cap176.57M
Sangamo Therapeutics focuses on genomic medicine, including gene editing and gene therapy, areas where Twist Bioscience's synthetic DNA products are relevant.
Adaptive Biotechnologies
ADPT
Mkt Cap693.12M
Adaptive Biotechnologies is engaged in the immune-driven medicine space, leveraging genomics and competing with Twist Bioscience in the use of synthetic DNA for immune system understanding.
Bionano Genomics
BNGO
Mkt Cap42.14M
Bionano Genomics provides tools for genomic analysis, competing in the broader genomics market where Twist Bioscience offers synthetic DNA solutions.

Analyst Ratings

52.25$Average Price Target
The highest estimate is $65.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
0%
Sell
13%

About

Health Technology
Biotechnology
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
Show more...
CEO
Emily Leproust
Employees
919
Country
US
ISIN
US90184D1000

Listings

XNAS
US
TWST
F
DE
0ME.F